NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME

Abstract: the present invention pertains to antigen recognizing constructs against tumor associated antigens (taa), in particular the taa serine protease inhibitor kazal-type 2 (spink2). the invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the tumor expressed antigen of the invention. the tcr of the invention, and spink2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of spink2 expressing cancerous diseases. further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Inventor(s): Claudia WAGNER, Leonie ALTEN, Sebastian BUNK, Dominik MAURER

CPC Classification: C07K16/26 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250154246